King's College London

Research portal

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017

Research output: Contribution to journalArticle

C. H. Smith, Z. K. Jabbar-Lopez, Z. Z. Yiu, T. Bale, A. D. Burden, L. C. Coates, M. Cruickshank, T. Hadoke, E. MacMahon, R. Murphy, C. Nelson-Piercy, C. M. Owen, R. Parslew, E. Peleva, E. Pottinger, E. J. Samarasekera, J. Stoddart, C. Strudwicke, V. Venning, R. B. Warren & 2 more L. S. Exton, M. F. Mohd Mustapa

Original languageEnglish
Pages (from-to)628-636
JournalBritish Journal of Dermatology
Volume177
Issue number3
Early online date22 Sep 2017
DOIs
Publication statusPublished - Sep 2017

Documents

  • Guidelines biologic therapy psoriasis_SMITH_Publishedonline17May2017_GREEN AAM

    Guidelines_biologic_therapy_psoriasis_SMITH_Publishedonline17May2017_GREEN_AAM.pdf, 1.31 MB, application/pdf

    22/09/2018

    Accepted author manuscript

    Other

    This is the peer reviewed version of an article which will be published in final form in British Journal of Dermatology (Wiley, 2017) at http://dx.doi.org/10.1111/bjd.15665. © Wiley, 2017. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

King's Authors

Abstract

The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. Biologic therapies have now been in use for over 10 years, and with accrued patient-years exposure and clinical experience, many areas that were covered in previous versions of the guideline are now part of the Summary of Product Characteristics (SPC) and/or routine care so that specific recommendations are redundant (see Toolkit A: Summary of licensed indications and posology for biologic therapy, in Supporting information 2). Therefore, in this update we focus on areas where there has been a major change in the evidence base or clinical practice, where practice is very varied and/or where clear consensus or guidelines are lacking (see section 3.1 in Supporting information 1). This article is protected by copyright. All rights reserved.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454